These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2406809)

  • 1. Treatment of generalized systemic sclerosis.
    Torres MA; Furst DE
    Rheum Dis Clin North Am; 1990 Feb; 16(1):217-41. PubMed ID: 2406809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of systemic sclerosis--a review.
    Ng SC; Clements PJ; Paulus HE
    Singapore Med J; 1990 Jun; 31(3):269-72. PubMed ID: 2203150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatments of progressive systemic sclerosis].
    Vayssairat M; Abdoucheli-Baudot N; Gaitz JP
    J Mal Vasc; 2001 Oct; 26(4):258-61. PubMed ID: 11679856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized and systemic scleroderma.
    Hawk A; English JC
    Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive therapies in systemic sclerosis.
    Riemekasten G; Sunderkötter C
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii49-51. PubMed ID: 16987836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scleroderma--clinical and pathological advances.
    Denton CP; Black CM
    Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis (scleroderma). Clinical management of its major complications.
    Legerton CW; Smith EA; Silver RM
    Rheum Dis Clin North Am; 1995 Feb; 21(1):203-16. PubMed ID: 7732169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of systemic sclerosis.
    Medsger TA
    Rheum Dis Clin North Am; 1989 Aug; 15(3):513-31. PubMed ID: 2672135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
    Merkel PA; Clements PJ; Reveille JD; Suarez-Almazor ME; Valentini G; Furst DE;
    J Rheumatol; 2003 Jul; 30(7):1630-47. PubMed ID: 12858472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on the treatment of systemic scleroderma].
    Priollet P; Cazalis P; Valleteau de Moulliac M
    J Mal Vasc; 1987; 12(2):213-7. PubMed ID: 3295097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
    Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
    Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment.
    Villela R; Yuen SY; Pope JE; Baron M;
    Arthritis Rheum; 2008 May; 59(5):706-13. PubMed ID: 18438906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of scleroderma peripheral vascular disease.
    Herrick A
    Rheum Dis Clin North Am; 2008 Feb; 34(1):89-114; vii. PubMed ID: 18329535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.